Mather Group’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
Other funds holding JAZZ
VPM
VCM
EC
Mather Group's JAZZ Position: Q1 2026 in Review
Mather Group opened a new position in Jazz Pharmaceuticals (JAZZ) in Q1 2026: 22 shares worth $4.16K. The stake represents ﹤0.01% of the portfolio and ranks #1602 among its holdings. This is a return to the name: Mather Group previously reported a position in JAZZ as recently as Q3 2025.
Mather Group first reported a position in JAZZ in Q1 2024 and has held it in 7 quarters since. The position peaked at $16.1K in Q2 2024. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Mather Group held 22 shares of Jazz Pharmaceuticals worth $4.16K as of Q1 2026.
- Jazz Pharmaceuticals was a new Mather Group position in Q1 2026.
- Jazz Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q1 2026, its #1602 holding.
- Mather Group first reported a position in Jazz Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
- Mather Group's Jazz Pharmaceuticals position peaked at $16.1K in Q2 2024.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Mather Group's 13F filing for Q1 2026, filed 13 Apr 2026.